Company: INSP
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001140361-25-009249
Chunk: 17

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 17
---
 Curet, Mr. Ellis, Ms. Garinois-Melenikiotou, Mr. McCormick, Mr. Mead, or Mr. Tansey, representing 8 of our 9 current directors and directors whose term will continue after the Annual Meeting, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors qualifies as “independent” as that term is defined under the rules of the NYSE. Our Board previously determined that each of Jerry C. Griffin, M.D. and Marilyn Carlson Nelson, directors who served on our Board through the 2024 annual meeting of stockholders, did not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and qualified as “independent” while serving as a director. Mr. Herbert, our President and CEO, is the only director who is not independent. In making these determinations, our Board of Directors considered the relationships that each non-employee director has with us and all other facts and circumstances our Board of Directors deemed relevant in determining their independence, including the director’s beneficial ownership of our common stock, the relationships of our non-employee directors with certain of our significant stockholders, and the organizations with which our non-employee directors have current relationships that may be pertinent to their independence. Board Committees Our Board of Directors historically had three standing committees: an Audit Committee, an Organization and Compensation Committee, and a Nominating and Corporate Governance Committee. On February 6, 2025, the Board approved a fourth standing committee of the Board, the Quality, Product Supply, and Technology Committee, to carry out responsibilities of the Board relating to oversight of the quality, safety, and supply of the Company’s products, legal and regulatory compliance matters, and the Company’s research, innovation, and technology initiatives and

| Inspire Medical Systems, Inc. |     | 16 |     | 2025 Proxy Statement |

TABLE OF CONTENTS

| CORPORATE GOVERNANCE |

programs. The Board believes the new committee will enhance the Board’s ability to carry out its oversight responsibilities in areas important to the Company’s current business and future growth. To accommodate the establishment of the new committee, current directors have taken on an additional committee assignment. The Board reviewed industry and peer benchmarking information and believes that expanded committees are aligned with best practices and may also allow for greater information sharing among directors and increased director awareness of committee priorities and strategic considerations across committees. The responsibilities of our